Clinical review report. Dolutegravir (Tivicay).

Clinical review report. Dolutegravir (Tivicay).

Show other versions (17)

The objective of this review is to evaluate the beneficial and harmful effects of Dolutegravir (DTG) at recommended doses in combination with other antiretroviral drugs for the treatment of HIV infection in antiretroviral drugs(ART)-naive and ART-experienced patients.

Saved in:
Bibliographic Details
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, August 2014.
Series:Common drug review clinical review report.
Subjects:
HIV Infections > drug therapy.
Anti-Retroviral Agents > administration & dosage.
Anti-Retroviral Agents > therapeutic use.
Drug Therapy, Combination > adverse effects.
Drug Evaluation.
HIV/AIDS.
STDs.
Canada.
Systematic Review.
Tables.
Online Access:http://www.ncbi.nlm.nih.gov/books/NBK534187/
Full text
http://www.ncbi.nlm.nih.gov/books/NBK534187/
Full text

MCPHS

Holdings details from MCPHS
Call Number: NCBI

Similar Items